A5051227977- Radiation Therapy and Dosimetry
- Hepatocellular Carcinoma Treatment and Prognosis
- Advanced Radiotherapy Techniques
- Medical Imaging Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging and Pathology Studies
- Lung Cancer Diagnosis and Treatment
- Hepatitis B Virus Studies
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Head and Neck Surgical Oncology
- Prostate Cancer Diagnosis and Treatment
- Boron Compounds in Chemistry
- Neuroscience and Neuropharmacology Research
- Liver Disease Diagnosis and Treatment
- Advanced MRI Techniques and Applications
- Esophageal Cancer Research and Treatment
- Prostate Cancer Treatment and Research
- Cancer, Hypoxia, and Metabolism
- Catalytic Processes in Materials Science
- Chemical Synthesis and Characterization
- Adenosine and Purinergic Signaling
- Radiomics and Machine Learning in Medical Imaging
- Neurological disorders and treatments
Hyogo Ion Beam Medical Center
2020-2024
Proton (Malaysia)
2007-2023
University of Tsukuba
2010-2023
Proton (United Kingdom)
2023
Imaging Center
2023
Ibaraki Prefectural Central Hospital
2012-2014
The University of Texas MD Anderson Cancer Center
2011
University of Tsukuba Hospital
2004-2011
Jikei University School of Medicine
1996-2005
Tokyo Metropolitan Institute of Gerontology
2003-2005
A 3D macroporous honeycomb-like ZnO/ZnCo<sub>2</sub>O<sub>4</sub> hybrid for CO sensing is reported.
Abstract This work reports the template‐free fabrication of mesoporous Al 2 O 3 nanospheres with greatly enhanced textural characteristics through a newly developed post‐synthesis “water‐ethanol” treatment aluminium glycerate followed by high temperature calcination. The proposed is highly advantageous as resulting exhibit 2–4 times higher surface area (up to 251 m g −1 ), narrower pore size distribution, and significantly lower crystallization than those obtained without any treatment. To...
Long‐term efficacy of proton beam therapy ( PBT ) remains unclear for patients with previously untreated hepatocellular carcinoma HCC ). We aimed to study the long‐term outcomes according Barcelona Clinic Liver Cancer BCLC staging classifications in . The major eligibility criteria this observational were an Eastern Cooperative Oncology Group performance status PS 0–2, Child–Pugh grade A or B, covered within irradiation field, and no massive ascites. total 66.0–77.0 GyE was administered...
Abstract Mesoporous materials with high surface area and pore volume have attracted significant attention as adsorbents they can provide extensive reaction sites for molybdenum (Mo) adsorption. In this study, we prepared mesoporous alumina (MA) using a soft-templated approach. By changing the applied calcination temperatures, mesostructural ordering, areas, crystallinity of MA be varied. Furthermore, effects these parameters on their adsorption properties been carefully investigated. The...
In this work, we have prepared alumina-embedded mesoporous silica and investigated their molybdenum (Mo) adsorption properties. To synthesize such materials, particles were firstly synthesized via a soft-templated approach followed by the introduction of aluminium butoxide into mesopores, which was converted alumina heat treatment at high temperatures. The obtained samples (Alx-MPS) characterized low- wide-angle X-ray diffractions, nitrogen adsorption-desorption isotherms, transmission...
Epigenetic modifications mediated by histone deacetylases (HDACs) play important roles in the mechanisms of different neurologic diseases and HDAC inhibitors (HDACIs) have shown promise therapy. However, pharmacodynamic profiles many HDACIs brain remain largely unknown due to lack validated methods for noninvasive imaging expression-activity. In this study, dynamic PET/CT was performed 4 rhesus macaques using [(18)F]FAHA, a novel substrate, [(18)F]fluoroacetate, major radio-metabolite fused...
Background and purposeWe investigated clinical outcomes of proton beam concurrent chemoradiotherapy (CCRT) for unresectable, locally advanced pancreatic cancer (LAPC) patients.Materials methodsRecords from 42 unresectable LAPC patients (21 male 21 female, 39–83 years old) with IIB/III staging 1/41 treated by CCRT were retrospectively reviewed. Twelve received a conventional 50 Gray equivalents (GyE) in 25 fractions protocol 30 others higher dose 54.0–67.5 GyE 25–33 fractions. Gemcitabine or...
The authors conducted a retrospective review to define the usefulness of proton beam therapy for patients who had hepatocellular carcinoma (HCC) with limited treatment options.Twenty-one HCC whom other modalities either were contraindicative or unfeasible because coexisting diseases and unfavorable conditions received therapy. Four renal failure, 2 severe heart disease, 9 cirrhosis, 1 patient aplastic anemia, dissecting abdominal aortic aneurysm before treatment, 4 bleeding tendency...